THE EXPERIENCE WITH ERIBULIN IN REAL CLINICAL PRACTICE FROM MOSCOW AND MOSCOW REGION

Introduction. Eribulin, an non-taxane microtubule inhibitor, has been registered in Russia for patients with locally advanced or metastatic breast cancer (mBC) who received at least one chemotherapy regimen for a advanced disease, previous therapy should include anthracyclines and taxanes in adjuvant or metastatic setting, except the patients who could not be prescribed these drugs. We present our experience with eribulin in real clinical practice in Moscow and the Moscow Region.

Patients and methods. We conducted a retrospective analysis of the experience with the use of eribulin in Moscow and the Moscow Region in 202 patients with mBC from January 2016 to February 2017 to assess the effectiveness and safety of the drug. All patients received previous therapy with anthracyclines and taxanes for locally advanced and / or metastatic cancer. The average age of patients at the time of inclusion in the analysis was 5 years (28–81). The status of the general condition on the ECOG 0-1 scale was registered in 81.3 % (100 / 123) of patients, the status of ECOG 2-3 in 18.7 % (23 / 123) of patients. The median of the number of courses of chemotherapy with eribulin is 4 (2–17). Patients received eribulin in 1-7 chemotherapy lines for metastatic disease. The average number of affected organs is 2 (1–5).

Results. Complete response (CR) was in 3 (2 %) patients. Partial response (PR) was in 24 (15.7 %) patients, stabilization of the disease – in 89 (58. 2 %). Progression of the disease was recorded in 37 (24.1 %) patients. The median of progression-free survival (PFS) on the therapy was 4.64 (95 % CI 2.97-6.87) months. Stabilization of the disease for more than 6 months was registered in 28 (18.3 %) patients. The most significant toxicity was neutropenia and polyneuropathy (21 patients (10.4 %) and 7 patients (3.5 %), respectively).

Dose reduction due to neutropenia was required by 26 patients (12.9 %). The objective response rate (ORR) depended on the chemotherapy line: in 1-3 lines the efficacy of the treatment was higher: the ORR was 21.6 %, compared to the 4th and subsequent lines – 12.3 %, respectively. With HER2-positive mBC, eribulin showed clinically significant results in combination with trastuzumab.

Conclusions. Our analysis confirms that eribulin has a predictable and manageable safety profile, is an effective drug for the treatment of patients with different subtypes of mBC in a real clinical setting.

1. Zlokachestvennye novoobrazovaniya v Rossii v 2016 godu (Zabolevaemost’ i Smertnost’). Eds. A. D. Kaprin, V. V. Starinskii, G. V. Petrova. Moscow, 2018. 250 p. (In Russ.).

2. Stenina M. B., Zhukova L. G., Koroleva I. A., Parokonnaya A. A., Semiglazova T. Y. et al. Practical recommendations for advanced breast cancer treatment. Malignance tumors. 2016. No. 4, Speсial Issue 2. P. 97–122 (In Russ.).

3. Kuznetsov G., Towle M. J., Cheng H. et al. Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389. Cancer Res. 2004. Vol. 64. P. 5760–5766.

4. Jordan M. A., Kamath K., Manna T. et al. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol. Cancer Ther. 2005. Vol. 4. P. 1086–1095.

5. Okouneva T., Azarenko O., Wilson L. et al. Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase. Mol. Cancer Ther. 2008. Vol. 7. P. 2003–2011.

6. Smith J. A., Wilson L., Azarenko O. et al. Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability. Biochemistry. 2010. Vol. 49. P. 1331–1337.

7. Funahashi Y., Okamoto K., Adachi Y. et al. Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models. Cancer Sci. 2014. Vol. 105. No. 10. P. 1334–1342.

8. Ueda S., Saeki T., Takeuchi H. et al. In vivo imaging of eribulin-induced reoxygenation in advanced breast cancer patients: a comparison to. Br. J. Cancer. 2016.

9. Cortes J., O’Shaughnessy J., Loesch D. et al. Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a Phase 3 open-label randomised study. Lancet. 2011. Vol. 377 (9769). P. 914–923.

10. Kaufman P. A., Awada A., Twelves C. et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J. Clin. Oncol. 2015. Vol. 33. P. 594–601.

11. Pivot X., Marme F., Koenigsberg R., Guo M., Berrak E., Wolfer A. Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy. Annals of Oncology. 2016. Vol. 27. P. 1525–31.

12. Blum J. L., Twelves C. J., Dutcus C. et al. Impact of the number of prior chemotherapy regimens on overall survival (OS) among subjects with locally recurrent or MBC treated with eribulin mesylate: results from the Phase III EMBRACE study. Presented at the 33rd Annual San Antonio Breast Cancer Symposium (SABCS), December 8-12, 2010, San Antonio, TX, USA. Cancer Res. Vol. 70, Issue 24 Supplement. P. P6-13–01.

13. Pivot X., Seock Ah Im, Guo M., Marm F. Subgroup analysis of patients with HER2negative metastatic breast cancer in the secondline setting from a phase 3, openlabel, randomized study of eribulin mesilate versus capecitabine. Breast Cancer. 2018. Vol. 25 (3). P. 370–374. doi: 10.1007/s12282-017-0826-4.

14. Instructions for the medical use of Halaven (Rev. 17.10.2017) (In Russ.).

15. Fabi A., Moscetti L., Ciccarese M. et al. Eribulin in heavily pretreated metastatic breast cancer patients and clinical / biological feature correlations: impact on the practice. Future Oncology. 2015. Vol. 11 (3). P. 431–438.

16. Manzyuk L. V., Kovalenko E. I., Artamonova E. V. Eribulin v lechenii metastaticheskogo raka molochnoi zhelezy. Voprosy onkologii. 2015. No. 2. P. 195–198 (In Russ.).

17. Bolotina L. V., Manzyuk L. V., Gorbunova V. A., Kovalenko E. I. et al. Rezul’taty pervogo retrospektivnogo dannykh po primeneniyu eribulina u patsientov s metastaticheskim rakom molochnoi zhelezy v usloviyakh real’noi klinicheskoi praktiki v Rossii. Sovremennaya Onkologiya. 2016. No. 18 (3). P. 27–32 (In Russ.).

18. Manzyuk L. V., Kovalenko E. I., Gorbunova V. A., Bolotina L. V. et al. Effektivnost’ i bezopasnost’ eribulina pri razlichnykh podtipakh raka molochnoi zhelezy: dannye iz real’noi klinicheskoi praktiki v Rossii. Zlokachestvennye opukholi. 2017. Vol. 7. No. 3. P. 44–54 (In Russ.).

19. Muss H., Cortes J., Vahdat L. T. et al. Eribulin monotherapy in patients aged 70 years and older with metastatic breast cancer. Oncologist. 2014. Vol. 19. P. 318–327.